Aetna analyst note projects AET/HUM merger approval and financial outlook

Aetna analyst note projects AET/HUM merger approval and financial outlook The passage is a routine investment thesis with no allegations, financial flows, or misconduct involving high‑profile officials. It merely forecasts a potential merger approval and stock performance, offering no actionable investigative leads. Key insights: Predicts AET/HUM deal approval by courts in January 2017; Forecasts 2018 EPS around $11.50, above consensus; Notes potential share repurchase of ~10% if deal falls through